Chemistry:Boserolimab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | MK-5890 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Boserolimab (MK-5890) is a monoclonal antibody in development for lung cancer. It is developed by Merck.[1][2][3]
References
- ↑ Peled, N.; Rodriguez-Abreu, D.; Bordoni, R.; Ellis, P.M.; Hochmair, M.; Müller, V.; Levchenko, E.; Zhou, H. et al. (December 2021). "114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)". Annals of Oncology 32: S1425. doi:10.1016/j.annonc.2021.10.132.
- ↑ Guelen, Lars; Fischmann, Thierry O; Wong, Jerelyn; Mauze, Smita; Guadagnoli, Marco; Bąbała, Nikolina; Wagenaars, Jozef; Juan, Veronica et al. (13 September 2022). "Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy". Journal for Immunotherapy of Cancer 10 (9): e005049. doi:10.1136/jitc-2022-005049. ISSN 2051-1426. PMID 36100308.
- ↑ Wickramarachchi, Dilki; Wagner, Julianne; Woo, Thomas; Ferrari, Federico; Steinmetz, Thomas; Helmy, Roy; Xu, Weifeng (25 January 2023). "A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies". The AAPS Journal 25 (1): 18. doi:10.1208/s12248-023-00783-9. PMID 36697923.
 |  |
